B+
Bull case
25%
Probability
Target price
$9.50
Analysis reference price unavailable
Analysis 2026-07-09 · RankAlpha Sentiment Codex
HELP
CybinFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The bull case is that HELP is entering a concentrated catalyst window: company materials point to a Q4 2026 HLP003 Phase 3 readout, a second Phase 3 study under way, and a cash position supplemented by the June 2026 offering [#PR-EARNINGS-2026-06-29]. The packet also shows a median analyst target of $31, implying upside if clinical execution de-risks materially, though target coverage count is unavailable and peer validation is weak.
Posture
Defensive
Lead driver
Value
What changed
1 setup hits (3d) with net bullish as of 2026-09-09.
What can break
Coverage is thin and recent news flow is sparse, increasing the chance that price discovery around catalysts remains volatile and sentiment-driven.
Momentum
99
Value
58
Sentiment
0
Setup hits (3d)
1 · Net Bullish
AI TargetsBase $6.00 · Bull $9.50 · Bear $3.25Analysis 2026-07-09; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-09 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Bullish
Target $41.22
Why
Momentum99 · Δ7d -0.1
Value58 · Δ7d 0.0
Sentiment0 · Δ7d -1.9
So what
Weak posture (Net Bullish). Prioritize risk control and patience.
Confirming evidence
- • 1 setup hits (3d) with net bullish as of 2026-09-09.
- • Value remains the lead driver in the composite, 7D delta 0.0.
Contradictions & invalidation
- • Coverage is thin and recent news flow is sparse, increasing the chance that price discovery around catalysts remains volatile and sentiment-driven.
- • Operating cash use rose with continued advancement of APPROACH, EMBRACE, EXTEND, HLP004, and HLP005, so runway still depends on disciplined trial execution and capital management [#PR-EARNINGS-2026-06-29].
- • The bear case is that this remains a low-coverage, high-uncertainty micro-cap biotech with negative deterministic priors, limited independent corroboration in the packet, and a thesis dominated by one major clinical readout.
Catalyst clock
2026-09-30
Post-offering cash reduces immediate financing pressure but dilution remains part of the setup
Lead driver: Value · See fundamentals
Momentum
99
9% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.7
Value
58
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.5
Sentiment
0
62% active weight
Current posture
7d trendSoftening
Δ7d
-1.9
Δ21d
-1.5
Why this grade
Composite grade F. Momentum 99.0 / Value 57.5 / Sentiment 0.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-07-09. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$6.00
Analysis reference price unavailable
Analysis 2026-07-09 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$3.25
Analysis reference price unavailable
Analysis 2026-07-09 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$1.38M
Beta
0.14
Shares Out
61.98M
P/E (TTM) · Derived
-0.0
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.01
Rev YoY
-
EPS YoY
-16.8%
Gross Margin
-
Op Margin
-
Net Debt
-$157.26M
Current Ratio
10.97
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data